Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesAbbotts XIENCE V Superior to TAXUS in Key Safety and Efficacy Measures in SPIRIT IV Trial
Abbott, 09/24/09
Late–breaking data from the SPIRIT IV trial demonstrated that Abbott's market–leading XIENCE V Everolimus Eluting Coronary Stent System achieved superiority in the key safety and efficacy measures of target lesion failure and target lesion revascularization compared to the TAXUS Express Paclitaxel–Eluting Coronary Stent System at one year. With 3,690 patients, the SPIRIT IV trial is one of the largest randomized clinical trials between two drug eluting stents.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/18/09
ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
ARIAD Pharmaceuticals, 12/18/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor